Adding certolizumab to chemotherapy and nivolumab for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether adding an extra medication, certolizumab, to the usual chemotherapy and an immunotherapy drug called nivolumab can help people with early-stage lung cancer before they have surgery. It aims to see if this combination shrinks the cancer more and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer that can be removed with surgery and you have not had treatment for it yet.
- You are 18 years old or older.
- You are generally able to care for yourself (performance status of 70 or higher on the Karnofsky scale).
- Your blood counts, liver, and kidney function are within acceptable ranges.
- You test negative for tuberculosis (TB) or have been treated for it.
- If you are of childbearing age, you agree to use effective birth control during the study and for at least 5 months after treatment ends.
- You do not have major autoimmune diseases like rheumatoid arthritis or inflammatory bowel disease, with some exceptions like well-controlled thyroid disease or type 1 diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Tislelizumab (an immunotherapy) combined with chemotherapy for people with advanced NSCLC who have already been helped by a different immunotherapy. It's a second-line option for those who did well on their first immunotherapy but now need another treatment.
This study tests a drug called pembrolizumab (an immunotherapy that helps your immune system fight cancer) combined with two chemotherapy drugs, without radiation. It is for people with stage III lung cancer that has not spread and has a high PD-L1 level. The goal is to see if this treatment can shrink or control the cancer better than the usual approach.
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
This study tests a combination of chemotherapy and immunotherapy in people with advanced non-small cell lung cancer that has spread or cannot be removed with surgery. The goal is to see how well this treatment works in patients with different levels of daily activity.
This study tests whether adding a type of chemotherapy called platinum-based chemo to an immunotherapy drug called tislelizumab helps people with advanced non-small cell lung cancer that has spread and has high PD-L1. The trial aims to see if this combination works better than immunotherapy alone in people with larger tumors.
This trial tests a lower dose of the immunotherapy drug nivolumab (Opdivo) combined with standard chemotherapy before surgery for patients with early-stage non-small cell lung cancer (NSCLC). The goal is to see if this combination shrinks the tumor and improves outcomes with fewer side effects.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.